Eric A. Welsh, Ph.D.
Institution:
Washington University, Saint Louis, St. Louis, MOArea:
Biochemistry, Biophysics, Medicinal ChemistryGoogle:
"Eric Welsh"Mean distance: 10.37 | S | N | B | C | P |
Parents
Sign in to add mentor| Garland R. Marshall | grad student | 2004 | Washington University | |
| (A set of computational tools for the analysis and prediction of protein structures.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Fang B, Izumi V, Rix LLR, et al. (2020) Lowering Sample Requirements to Study Tyrosine Kinase Signaling using Phosphoproteomics with the TMT Calibrator Approach. Proteomics. e2000116 |
| Stewart PA, Welsh EA, Slebos RJC, et al. (2019) Proteogenomic landscape of squamous cell lung cancer. Nature Communications. 10: 3578 |
| Sumi NJ, Ctortecka C, Hu Q, et al. (2019) Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets. Cell Chemical Biology |
| Gordian E, Welsh EA, Gimbrone N, et al. (2019) Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer. Oncotarget. 10: 810-824 |
| Koomen DC, Meads MB, Magaletti DM, et al. (2019) Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma Blood. 134: 5534-5534 |
| Burger KL, Meads MB, Berglund A, et al. (2019) A CK1δ/CK1ε Regulated Metabolic Circuit Is a Therapeutic Vulnerability for Multiple Myeloma Blood. 134: 5537-5537 |
| Renatino-Canevarolo R, Sudalagunta PR, Coelho Siqueira Silva MD, et al. (2019) Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance Blood. 134: 5544-5544 |
| Majumder A, Zhang G, Adhikari E, et al. (2019) Abstract 4543: Proteomic characterization of AXL kinase inhibitors and signaling pathways Cancer Research. 79: 4543-4543 |
| Rix LLR, Sumi NJ, Bryant AT, et al. (2019) Abstract C110: Cancer associated fibroblast-derived IGF-binding proteins augment osimertinib activity in EGFR-mutant NSCLC cells Molecular Cancer Therapeutics. 18 |
| Palve V, Knezevic C, Luo Y, et al. (2019) Abstract B021: PARP16 is a novel target of talazoparib which contributes to synergy with adavosertib in SCLC Molecular Cancer Therapeutics. 18 |